To be or not to be B7

Journal of Clinical Investigation

Volumn 116, Issue 10, 2006, Pages 2590-2593

  Zang, Xingxing ^a   Allison, James P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT RECEPTOR; PROTEIN COMPLEMENT RECEPTOR IG; PROTEIN VSIG4; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

EVOLUTION; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; EVOLUTION, MOLECULAR; GENE EXPRESSION; HUMANS; IMMUNOGLOBULINS; LYMPHOCYTE ACTIVATION; MICE; MODELS, IMMUNOLOGICAL; RECEPTORS, COMPLEMENT; RECEPTORS, COMPLEMENT 3B; T-LYMPHOCYTES;

EID: 33749443579     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30103     Document Type: Review

References (16)

1. Korman, A.J., Peggs, K.S., and Allison, J.P. 2006. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 90:297-339.
2. Peggs, K.S., Quezada, S.A., Korman, A.J., and Allison, J.P. 2006. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. 18:206-213.
3. Okazaki, T., and Honjo, T. 2006. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 27:195-201.
4. Barber, D.L., et al. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 439:682-687.
5. Vogt, L., et al. 2006. VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J. Clin. Invest. 116:2817-2826. doi:10.1172/JCI25673.
6. Langnaese, K., Colleaux, L., Kloos, D.U., Fontes, M., and Wieacker, P. 2000. Cloning of Z39Ig, a novel gene with immunoglobulin-like domains located on human chromosome X. Biochim. Biophys. Acta. 1492:522-525.
7. Helmy, K.Y., et al. 2006. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell. 124:915-927.
8. Kim, J.K., et al. 2005. Characterization of monoclonal antibody specific to the Z39Ig protein, a member of immunoglobulin superfamily. Immunol. Lett. 99:153-161.
9. Holers, V.M., Kinoshita, T., and Molina, H. 1992. The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function. Immunol. Today. 13:231-236.
10. Roozendaal, R., and Carroll, M.C. 2006. Emerging patterns in complement-mediated pathogen recognition. Cell. 125:29-32.
11. Gray, J.D., and Horwitz, D.A. 1988. Lymphocytes expressing type 3 complement receptors proliferate in response to interleukin 2 and are the precursors of lymphokine-activated killer cells. J. Clin. Invest. 81:1247-1254.
12. Claesson, M.H., and Miller, R.G. 1985. Functional heterogeneity in allospecific cytotoxic T lymphocyte clones. II. Development of syngeneic cytotoxicity in the absence of specific antigenic stimulation. J. Immunol. 134:684-690.
13. Yaskanin, D.D., Thompson, L.F., and Waxman, F.J. 1992. Distribution and quantitative expression of the complement receptor type 1 (CR1) on human peripheral blood T lymphocytes. Cell. Immunol. 142:159-176.
14. Wagner, C., et al. 2006. The complement receptor 1, CR1 (CD35), mediates inhibitory signals in human T-lymphocytes. Mol. Immunol. 43:643-651.
15. Hong, K., et al. 1991. Reconstitution of C5 convertase of the alternative complement pathway with isolated C3b dimer and factors B and D. J. Immunol. 146:1868-1873.
16. Brown, E.J. 1991. Complement receptors and phagocytosis. Curr. Opin. Immunol. 3:76-82.